Business

Add as a preferred source on Google

Chemours Posts $196 Million Q3 Profit, Including $150 Million PFAS Receipt

Third-quarter 2026 sales rose 3% to $1.54 billion. The company expects sales to fall 5% to 10% in the fourth quarter.

Updated 2 min read
Pipes and storage tanks stand at Chemours' Chambers Works complex in Deepwater, New Jersey / EconoTimes.ai
Pipes and storage tanks stand at Chemours' Chambers Works complex in Deepwater, New Jersey / EconoTimes.ai

The Chemours Company reported $196 million in net income for the third quarter of 2026, including a $150 million payment under a PFAS insurance memorandum of understanding, while sales grew 3% to $1.54 billion. The payment lifted reported profit, which was $46 million in the year-earlier quarter; adjusted net income was $31 million, up from $26 million. Chemours disclosed the results in its earnings release.

The insurance proceeds were connected to the finalization of a judicial consent order with New Jersey. Chemours recorded the $150 million as a reduction in selling, general and administrative expenses. Adjusted net income and adjusted EBITDA are non-GAAP measures. Adjusted EBITDA increased to $200 million from $189 million.

Pricing helped lift overall sales, while lower volumes and currency effects partly offset the gain. Titanium Technologies revenue increased 11% to $680 million, and its adjusted EBITDA rose to $85 million from $25 million. The company cited higher global prices and a small increase in volumes.

Advanced Performance Materials sales grew 8% to $337 million. Within the segment, Performance Solutions revenue rose 26% to $153 million; Chemours linked the increase to demand from data center and semiconductor markets.

Thermal & Specialized Solutions was a weaker area. Sales fell 9% to $510 million, and adjusted EBITDA dropped 30% to $136 million. Chemours said lower North American sales of Opteon refrigerant blends for stationary air conditioning and higher costs weighed on results. The year-earlier period had received a boost from initial aftermarket channel fill associated with the U.S. AIM Act technology transition.

For the fourth quarter, Chemours expects sales to decline 5% to 10% from the prior quarter and adjusted EBITDA of $160 million to $185 million. For full-year 2026, it projected sales growth of about 2% over 2025 and adjusted EBITDA between $775 million and $800 million.

Chemours reported net debt of $3.2 billion and net leverage of about 4.3 times trailing 12-month adjusted EBITDA as of Sept. 30. It expects leverage below 4.2 times at year-end. President and CEO Denise Dignam said the company remained focused on “disciplined execution” amid softer economic conditions and challenges in the stationary air-conditioning aftermarket.

Related articles

View all